L-type Ca++ CP β1 inhibitors belong to a class of chemical compounds that have attracted attention in the field of pharmacology and biomedical research due to their role in modulating the activity of the L-type calcium channel auxiliary subunit known as CP β1. L-type calcium channels are crucial for regulating calcium ion influx in various cells, including cardiac myocytes and neurons, and play a fundamental role in processes such as muscle contraction, neurotransmitter release, and gene expression. The CP β1 subunit, also referred to as CACNB1, serves as a regulatory component of these channels, influencing their biophysical properties and cellular localization. L-type Ca++ CP β1 inhibitors are designed to interact with the CP β1 subunit, thereby altering its influence on L-type calcium channel function.
The mechanism of action of L-type Ca++ CP β1 inhibitors typically involves their binding to the CP β1 subunit, often at specific binding sites or domains. This interaction can lead to conformational changes or modifications in the CP β1 subunit, which in turn affect its regulatory role in L-type calcium channels. Consequently, these inhibitors can modulate calcium ion influx and, by extension, influence cellular processes that rely on L-type calcium channel activity. The study of L-type Ca++ CP β1 inhibitors is of considerable significance in elucidating the intricate mechanisms that govern calcium signaling in various cell types. It provides valuable insights into the molecular underpinnings of calcium channel regulation, paving the way for a deeper understanding of cellular physiology and the development of novel research tools.
SEE ALSO...
Items 11 to 11 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Mibefradil dihydrochloride | 116666-63-8 | sc-204083 sc-204083A | 10 mg 50 mg | $209.00 $848.00 | 4 | |
Mibefradil, though no longer clinically used, could theoretically alter the expression of L-type calcium channel subunits. |